Obinutuzumab for certain Chinese lymphomas in real-world care
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how obinutuzumab works in people in routine care who have specific types of lymphoma. It specifically includes adults in China who started treatment with otuzumab during a set time window, to see outcomes in real-world patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older when treatment starts in this study
- Your diagnosis is grade 1–3a follicular lymphoma or marginal zone lymphoma
- Your lymphoma is newly diagnosed, or you have come back (relapsed), or did not respond (refractory)
- You started otuzumab treatment between June 2021 and April 2023
- You are not currently in, and do not plan to join, any other interventional clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of two targeted drugs (orelabrutinib and obinutuzumab) as a first treatment for marginal zone lymphoma that has returned or progressed after local therapy. The goal is to see if this combination works better than current options.
This Phase 2 study tests how well obinutuzumab (an antibody medicine) combined with chemotherapy works for people whose CD20-positive B-cell lymphoma has come back or didn’t respond to initial treatment. It may help by attacking lymphoma cells that carry the CD20 marker.
This study looks at how well a drug called polatuzumab works for people with a type of lymphoma (DLBCL) in everyday medical practice in China. It is for patients who are older, have other health problems, or whose lymphoma came back after or did not respond to treatment.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
Hear when a new Lymphomas Non-Hodgkin's B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.